Formuepleje A/S’s Edwards Lifesciences EW Stock Holding History

Formuepleje A/S’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-105,673	Closed	-$10.1M	–	70
2024 Q1	$10.1M	Buy	+105,673	New	+$8.88M	0.57%	51
2023 Q4	–	Sell	-114,621	Closed	-$8.01M	–	91
2023 Q3	$8.01M	Buy	114,621 +1,895	+2%	+$152K	0.74%	40
2023 Q2	$10.6M	Sell	112,726 -5,376	-5%	-$467K	0.93%	29
2023 Q1	$9.69M	Buy	118,102 +33,784	+40%	+$2.66M	0.71%	39
2022 Q4	$6.25M	Buy	84,318 +46,681	+124%	+$3.6M	0.53%	59
2022 Q3	$3.21M	Buy	+37,637	New	+$3.62M	0.26%	71

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Formuepleje A/S's EW Position: Q2 2024 in Review

Formuepleje A/S sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 105,673 shares — an estimated $10.1M sold.

Formuepleje A/S first reported a position in EW in Q3 2022 and held it in 6 quarters. The position peaked at $10.6M in Q2 2023. 1,296 funds tracked by Wall St. Rank hold EW as of Q2 2024.

Formuepleje A/S reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
Formuepleje A/S sold 105,673 Edwards Lifesciences shares in Q2 2024, an estimated $10.1M.
Formuepleje A/S first reported a position in Edwards Lifesciences in Q3 2022 and held it in 6 quarters.
Formuepleje A/S's Edwards Lifesciences position peaked at $10.6M in Q2 2023.
1,296 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on Formuepleje A/S's 13F filing for Q2 2024, filed 27 Aug 2026.